Seven-year outcomes study data demonstrated statistical superiority of Zimmer Biomet’s Mobi-C® Cervical Disc Prosthesis vs. 2-level anterior cervical discectomy and fusion (ACDF) in overall success. The prospective, randomized, controlled trial was conducted as an FDA-regulated Investigational Device Exemption clinical trial.
Overall success required improvement in Neck Disability Index, no secondary surgical interventions at index levels and absence of major complications (e.g., radiographic failure, neurological failure or adverse events). Previous studies of Mobi-C include
- Five-year results of Mobi-C cost utility analysis
- Independent peer-reviewed 5-year follow-up: 2-level CDR vs. ACDF
- No evidence of a reduction in efficacy with an increase from 1 to 2 treated levels
Mobi-C was the first cervical disc prosthesis approved by FDA for reconstruction of the cervical disc at both one and two levels. Medtronic’s Prestige LP cervical disc, for which 7-year data vs. ACDF is also available, received FDA approval for 2-level applications in 3Q16.
Sources: Zimmer Biomet, Inc.; ORTHOWORLD Inc.
Seven-year outcomes study data demonstrated statistical superiority of Zimmer Biomet's Mobi-C® Cervical Disc Prosthesis vs. 2-level anterior cervical discectomy and fusion (ACDF) in overall success. The prospective, randomized, controlled trial was conducted as an FDA-regulated Investigational Device Exemption clinical trial.
Overall success...
Seven-year outcomes study data demonstrated statistical superiority of Zimmer Biomet’s Mobi-C® Cervical Disc Prosthesis vs. 2-level anterior cervical discectomy and fusion (ACDF) in overall success. The prospective, randomized, controlled trial was conducted as an FDA-regulated Investigational Device Exemption clinical trial.
Overall success required improvement in Neck Disability Index, no secondary surgical interventions at index levels and absence of major complications (e.g., radiographic failure, neurological failure or adverse events). Previous studies of Mobi-C include
- Five-year results of Mobi-C cost utility analysis
- Independent peer-reviewed 5-year follow-up: 2-level CDR vs. ACDF
- No evidence of a reduction in efficacy with an increase from 1 to 2 treated levels
Mobi-C was the first cervical disc prosthesis approved by FDA for reconstruction of the cervical disc at both one and two levels. Medtronic’s Prestige LP cervical disc, for which 7-year data vs. ACDF is also available, received FDA approval for 2-level applications in 3Q16.
Sources: Zimmer Biomet, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.